Cabozantinib COSMIC-311



Cabozantinib COSMIC-311 Cabozantinib COSMIC-311 PRELIMINARY SCORE **FINAL SCORE** CURATIVE **CURATIVE** Overall Survival / Disease-Free Survival / Pathological Complete Response **NON-CURATIVE NON-CURATIVE** Overall Survival **ADJUSTMENTS** Quality of life Progression-Free Survival Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate Serious and disabling adverse effects Overall Response Rate / Duration of Response More serious and disabling adverse events observed Overall Survival / Disease-Free Survival / Pathological Complete Response INFORMATION Other adjustments Tumour type: Endocrine Tumours Therapeutic Indication: Treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma, refractory or not eligible to radioactive iodine who have progressed during or after prior systemic therapy Experimental Arm: Cabozantinib Control Arm: Placebo



© 2023 | European Society for Medical Oncology | ESMO - MCBS 1.1 | All rights reserved worldwide.